<span item_type="fundamental" item_id="ea7d0965c392bd84b999d1ba04992c25" counter_id="ST/US/MPLT" env="prod"></span><span item_type="announcement" item_id="589908097683098241" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -37.18.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -33.05 M.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li>The financial results for the third quarter ended September 30, 2025, were announced by MapLight Therapeutics, Inc. on December 4, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-20251204.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li>Research and development expenses were $27.1 million for the third quarter of 2025, compared to $16.8 million for the third quarter of 2024, reflecting increases in clinical trial expenses, employee-related expenses, and formulation and CMC expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_1.htm"></span></li><li>General and administrative expenses were $4.4 million for the third quarter of 2025, compared to $4.1 million for the third quarter of 2024, primarily due to increases in legal and consulting fees.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_1.htm"></span></li><li>Net loss was - $29.4 million for the third quarter of 2025, compared to - $19.0 million for the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_1.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>No specific cash flow data was provided in the reference text.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-20251204.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li>No unique financial indicators were provided in the reference text.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-20251204.htm"></span></li></ul><h4>Cash and Investments</h4><ul><li>The company ended the quarter with $227.2 million in cash, cash equivalents, and short-term investments.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_1.htm"></span></li></ul><h4>IPO and Private Placement</h4><ul><li>Completed $296.5 million initial public offering and private placement in October 2025, with net proceeds of $269.8 million after deducting underwriting discounts and commissions, placement agent fees, and estimated offering expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_1.htm"></span></li></ul><h4>Financial Position</h4><ul><li>MapLight Therapeutics, Inc. has a strong financial position with approximately $497 million in pro forma cash as of September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="3" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_2.htm"></span></li></ul><h4>Cash Composition</h4><ul><li>The pro forma cash is based on a cash, cash equivalents, and short-term investments balance of approximately $227.2 million as of September 30, 2025, and net proceeds from IPO and concurrent private placement of approximately $269.8 million after deducting underwriting discounts and commissions, placement agent fees, and offering expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="3" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_2.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>The company expects its current cash, cash equivalents, and short-term investments, together with the net proceeds from the IPO and concurrent private placement, to be sufficient to fund operations through 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_1.htm"></span></li><li>Topline results from Phase 2 trials for ML-007C-MA in schizophrenia and Alzheimer’s disease psychosis are expected in the second half of 2026 and 2027, respectively.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_1.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="3" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_2.htm"></span></li><li>The company plans to complete IND-enabling studies for ML-021 in the second half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_1.htm"></span></li><li>MapLight Therapeutics plans to continue advancing its early-stage pipeline and expects to achieve key milestones with its strong financial position.<span class="superscript" item_id="0" item_type="announcement_file" value="3" url="https://www.sec.gov/Archives/edgar/data/1770069/000119312525307450/mplt-ex99_2.htm"></span></li></ul>

MapLight Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0